Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences' Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd.

Related Keywords

China ,Chengdu ,Sichuan ,Germany ,Taiwan ,Shanghai ,United States ,Hong Kong ,Shenzhen ,Guangdong ,Boston ,Massachusetts ,Beijing ,Heidelberg ,Baden Wüberg ,Macau ,Chinese ,Haimen Jiangsu ,Chipscreen Newway Biosciences ,Chipscreen Biosciences ,Yuelei Shen ,Eucure Biopharma ,Chipscreen Newway ,Xianping Lu ,Eucure Beijing Biopharma Co Ltd ,Drug Administration ,Biocytogen Pharmaceuticals Beijing Co Ltd ,Head Of The Center ,Shenzhen Chipscreen Biosciences Co Ltd ,Greater China ,Mainland China ,Bin Liu ,Fc Silent Igg ,China Food ,Chengdu Hi Tech Zone ,Media Contact ,Biocytogen Pharmaceuticals ,Iocytogen Pharmaceuticals Beijing Co ,Td ,Ispecific Antibody Yh008 ,R Yuelei Shen ,R Xianping Lu ,